

Stichting The Hodgkin Lymphoma MRD Consortium Foundation
Heemstede
Report on the annual accounts 2025

Nieuwegein, August 27, 2026

Table of contents

	Page
Accountants report	
Accountant's compilation report	3
General	5
Financial statements	
Balance sheet as at 31 December 2025	7
Income statement for the year 2025	9
Notes to the financial statements	10
Notes to the balance sheet as at 31 December 2025	12
Notes to the income statement for the year 2025	13

ACCOUNTANTS REPORT

To the Management Board of
Stichting The Hodgkin Lymphoma MRD Consortium Foundation
To the attention of Prof. Dr. J.M. Zijlstra-Baalbergen
Herenweg 152 A
2101 MT Heemstede

Dear Board,

We hereby offer you the report concerning the annual report 2025 for Stichting The Hodgkin Lymphoma MRD Consortium Foundation, Heemstede.

ACCOUNTANT'S COMPILATION REPORT

The financial statements of Stichting The Hodgkin Lymphoma MRD Consortium Foundation, Zeist, have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at 31 December 2025 and the income statement for the year 2025 for the year then ended with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, 'Compilation engagements', which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting The Hodgkin Lymphoma MRD Consortium Foundation. We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the 'Verordening Gedrags- en Beroepsregels Accountants' (VGBA). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

Nieuwegein, 27 August 2026

Maatschap db-adviseurs



Drs. A. Maartense-Bassie RA

GENERAL

Members of the board

Members of the board:

- Prof. Dr. J.M. Zijlstra-Baalbergen (Chairman)
- Prof. Dr. P. Borchmann (Member)
- Prof. Dr. J.A. Radford (Member)

Activities

The activities of Stichting The Hodgkin Lymphoma MRD Consortium Foundation, having its legal seat at Zeist, primarily consist of the following:

To Promote research and treatment of patients with Hodgkin Lymphoma employing the development of new technologies to detect minimal residual disease, but in a broader sense not limited to this.

Profit appropriation

The result 2024 is in conformity with the resolution of the Board, transferred to profit and loss account.

FINANCIAL STATEMENTS

BALANCE SHEET AS AT 31 DECEMBER 2025*(After proposal distribution of result)*

	<u>2025</u>		<u>2024</u>	
	€	€	€	€
ASSETS				
Current assets				
Receivables		4.514		7.063
Cash and cash equivalents		406.130		460.131
		<u>410.644</u>		<u>467.194</u>

	<u>2025</u>		<u>2024</u>	
	€	€	€	€
EQUITY AND LIABILITIES				
Foundation capital				
Share capital		-		-
Other reserves		<u>408.604</u>		<u>406.325</u>
Current liabilities				
Trade payables	-		20	
Other liabilities and accrued expenses	<u>2.040</u>		<u>60.849</u>	
		2.040		60.869
		<u>410.644</u>		<u>467.194</u>

INCOME STATEMENT FOR THE YEAR 2025

	2025		2024	
	€	€	€	€
Other operating expenses		<u>2.026</u>		<u>221.180</u>
Total of operating result		-2.026		-221.180
Other interest and similar income	4.563		11.349	
Interest and similar expenses	<u>-258</u>		<u>-149</u>	
Financial income and expense		<u>4.305</u>		<u>11.200</u>
Total of result after tax		<u><u>2.279</u></u>		<u><u>-209.980</u></u>

NOTES TO THE FINANCIAL STATEMENTS

Entity information

Registered office, legal form and registration number at the Chamber of Commerce

The actual address of Stichting The Hodgkin Lymphoma MRD Consortium Foundation is Herenweg 152 A, 2101 MT in Heemstede, the registered office of the legal entity is Zeist. Stichting The Hodgkin Lymphoma MRD Consortium Foundation is registered at the Chamber of Commerce under number 71042882.

General accounting principles

The accounting standards used to prepare the financial statements

The financial statements are drawn up in accordance with the provisions of Title 9, Book 2 of the Dutch Civil Code and the Dutch Accounting Standards, as published by the Dutch Accounting Standards Board ('Raad voor de Jaarverslaggeving').

Assets and liabilities are generally valued at historical cost, production cost or at fair value at the time of acquisition. If no specific valuation principle has been stated, valuation is at historical cost.

Accounting principles

Receivables

Receivables are initially valued at the fair value of the consideration to be received, including transaction costs if material. Receivables are subsequently valued at the amortised cost price. If there is no premium or discount and there are no transaction costs, the amortised cost price equals the nominal value of the accounts receivable. Provisions for bad debts are deducted from the carrying amount of the receivable.

Cash and cash equivalents

Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is valued at nominal value.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

Other operating expenses

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.

NOTES TO THE BALANCE SHEET AS AT 31 DECEMBER 2025

Current assets

	<u>2025</u>	<u>2024</u>
	€	€
Receivables		
Accruals and prepaid expenses	<u>4.514</u>	<u>7.063</u>
Cash and cash equivalents		
Triodos accounts	<u>406.130</u>	<u>460.131</u>

Current liabilities

<u>Trade payables</u>		
Accounts payable	<u>-</u>	<u>20</u>
<u>Other liabilities and accrued expenses</u>		
Audit and consultancy costs	2.040	6.099
Invoices to be received	<u>-</u>	<u>54.750</u>
	<u>2.040</u>	<u>60.849</u>

NOTES TO THE INCOME STATEMENT FOR THE YEAR 2025

	2025 €	2024 €
Other operating expenses		
Cost research	-	219.000
Office expenses	115	168
General expenses	1.911	2.012
	<u>2.026</u>	<u>221.180</u>
Cost research		
Costs Research Liqomics	<u>-</u>	<u>219.000</u>
Office expenses		
Automation expenses	<u>115</u>	<u>168</u>
General expenses		
Conference costs	-	149
Audit costs	1.930	1.863
Other general expenses	-19	-
	<u>1.911</u>	<u>2.012</u>
Received bank interest		
Received bank interest	<u>4.563</u>	<u>11.349</u>
Interest and similar expenses		
Paid bank interest	<u>258</u>	<u>149</u>

Heemstede, August 27, 2026

Stichting The Hodgkin Lymphoma MRD Consortium Foundation